Author/Authors :
Shoaei، Parisa نويسنده Infectious Diseases and Tropical Medicine Research center, Isfahan University of Medical Sciences, Isfahan , , Zeidabadinejad، Laleh نويسنده Infectious Diseases and Tropical Medicine Research center, Isfahan University of Medical Sciences, Isfahan , , Hassannejad، Razieh نويسنده Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan , , Ataei، Behrooz نويسنده Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan , , Yaran، Majid نويسنده Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran , , Kassaian، Nazila نويسنده Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan , , Nokhodian، Zary نويسنده Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan , , Foroughifar، Maryam نويسنده Infectious Diseases and Tropical Medicine Research center, Isfahan University of Medical Sciences, Isfahan ,
Abstract :
Objectives: Patients with Hepatitis C Virus infection are at high risk
of getting hepatitis A virus. Hepatitis A virus is an important widespread
virus that usually causes more severe medical consequences in
patients with chronic liver disease. The purpose of this study was to
evaluate prevalence of Hepatitis A Virus antibody in patients with
chronic HCV in Isfahan province, Iran.
Methods: A cross-sectional study was carried out on 117 patients with
chronic hepatitis C virus from spring 2010 to spring 2011. Subject’s
characteristics such as age, gender, education, genotype of HCV infection
and history of intravenous drug use were collected by questionnaire
and studied. Statistical analysis was done by SPSS software (version
19.0. 2010, SPSS) using Chi-square test, Fisher Exact tests and
Cochran-Armitage trend test.
Results: The mean age of the subjects was 33.18 ± 10.97 years. The
seroprevalence of HAV was 94.9% in patients with chronic HCV. The
prevalence of anti-HAV increased nearly as age increased. But, there
was no statistically significant difference in HAV positive rate according
to the age groups (P = 0.242) and other patient’s characteristics.
Conclusions: According to the high HAV immunity in our study and
less severe form of HAV infection, vaccination was not required in
these patients. However, hepatitis A vaccination program should be
performed in HAV seronegative patients with HCV to produce an
adequate immune response.
